Could earlier aspirin save lives in sickle cell pregnancies?

NCT ID NCT06417411

Ongoing Disease control Sponsor: Instituto Nacional de Investigacao em Saude, Angola Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at whether starting daily low-dose aspirin in the first trimester (weeks 1–12) is safer and more effective than starting in the second trimester (weeks 13–27) for pregnant women with sickle cell disease. Researchers will track maternal deaths, preterm births, and late miscarriages. The goal is to find the best timing to reduce serious pregnancy complications in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin 100 mg
What this could lead to: If starting aspirin earlier reduces complications, it could offer a simple, low-cost way to improve pregnancy outcomes in women with sickle cell disease.
What could go wrong: This is an early-phase study, so results may not be conclusive. Aspirin carries bleeding risks, and the benefit may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-ECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pregnancy disorder sickle cell disease preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRE-ECLAMPSIA PREGNANCY COMPLICATIONS PREGNANCY RELATED SICKLE CELL DISEASE

Contacts and locations

Show contact details

Locations

Instituto Nacional de Investigação Em Saúde

Luanda, Luanda Province, 00000, Angola

More trials for these conditions

Other studies related to the condition(s) this trial covers.